Tower Research Capital (TRC)’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-458	Closed	-$60K	–	6040
2020 Q4	$60K	Sell	458 -170	-27%	-$15K	﹤0.01%	2926
2020 Q3	$32K	Sell	628 -1,042	-62%	-$46.8K	﹤0.01%	3711
2020 Q2	$80K	Buy	+1,670	New	+$77.7K	﹤0.01%	2651
2019 Q4	–	Sell	-512	Closed	-$18K	–	4772
2019 Q3	$18K	Buy	+512	New	+$20K	﹤0.01%	2560
2019 Q1	–	Sell	-2,325	Closed	-$32K	–	4582
2018 Q4	$32K	Buy	2,325 +247	+12%	+$3.12K	﹤0.01%	1600
2018 Q3	$21K	Buy	+2,078	New	+$34.2K	﹤0.01%	2326

Tower Research Capital (TRC)'s EIDX Position: Q1 2021 in Review

Tower Research Capital (TRC) sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 458 shares — an estimated $60K sold.

Tower Research Capital (TRC) first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $80K in Q2 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Tower Research Capital (TRC) reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Tower Research Capital (TRC) sold 458 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $60K.
Tower Research Capital (TRC) first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Tower Research Capital (TRC)'s Eidos Therapeutics, Inc. Common Stock position peaked at $80K in Q2 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.